| Summary: | Aim: Due to extensive treatment switching in the MAVORIC trial, lack of UK regulatory licence for the
comparator, overall survival (OS) with mogamulizumab was compared with patients with previously
treated advanced mycosis fungoides/S ´ ezary syndrome (MF/SS) in real-world setting. Design, setting &
participants: Data were from the Hospital Episode Statistics database (all patients in NHS secondary
care system in 2009–2019). Patients were selected according to trial inclusion criteria, then trial and HES
samples were matched on selected variables with significant imbalance. Outcomes: The analysis indicated
significant improvement in OS for mogamulizumab treatment compared with UK clinical practice (hazard
ratio: 0.36, 95% CI: 0.24, 0.53). Conclusion: Results suggest an OS advantage for patients with advanced
MF/SS treated with mogamulizumab in MAVORIC trial compared with UK clinical practice.
|
|---|